Restoration of hematopoiesis

Restoration of hematopoiesis refers to the re-establishment of normal blood cell production by hematopoietic stem and progenitor cells (HSPCs) after disruption from disease, chemotherapy, radiation, or genetic defects. This process involves the activation and regulation of complex molecular mechanisms, predominantly signaling pathways (such as JAK/STAT, NF-κB, mTOR) and transcriptional/epigenetic controls within HSPCs. Therapeutic strategies to restore hematopoiesis include administration of hematopoietic growth factors, manipulation of the bone marrow niche, and targeting cis-regulatory genomic elements. While restoration of hematopoiesis is a vital clinical goal, it is not itself a discrete molecular target or receptor; rather, it encompasses the integrated action of multiple molecular pathways within stem and progenitor cells[1][3][4].

Stimulation of hematopoietic stem/progenitor cell proliferation and differentiation; Activation of relevant signaling pathways (e.g., JAK/STAT, NF-κB, mTOR); Targeting cis-regulatory genetic elements or epigenetic modifications to alter gene expression in HSPCs